Top

Molecular Cancer

Published in:

Open Access 01-12-2021 | Research

CircPTPRA blocks the recognition of RNA N⁶-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression

Authors: Fei Xie, Chao Huang, Feng Liu, Hui Zhang, Xingyuan Xiao, Jiayin Sun, Xiaoping Zhang, Guosong Jiang

Published in: Molecular Cancer | Issue 1/2021

Abstract

Background

Circular RNAs (circRNAs) have been found to have significant impacts on bladder cancer (BC) progression through various mechanisms. In this study, we aimed to identify novel circRNAs that regulate the function of IGF2BP1, a key m⁶A reader, and explore the regulatory mechanisms and clinical significances in BC.

Methods

Firstly, the clinical role of IGF2BP1 in BC was studied. Then, RNA immunoprecipitation sequencing (RIP-seq) analysis was performed to identify the circRNAs interacted with IGF2BP1 in BC cells. The overall biological roles of IGF2BP1 and the candidate circPTPRA were investigated in both BC cell lines and animal xenograft studies. Subsequently, we evaluated the regulation effects of circPTPRA on IGF2BP1 and screened out its target genes through RNA sequencing. Finally, we explored the underlying molecular mechanisms that circPTPRA might act as a blocker in recognition of m⁶A.

Results

We demonstrated that IGF2BP1 was predominantly binded with circPTPRA in the cytoplasm in BC cells. Ectopic expression of circPTPRA abolished the promotion of cell proliferation, migration and invasion of BC cells induced by IGF2BP1. Importantly, circPTPRA downregulated IGF2BP1-regulation of MYC and FSCN1 expression via interacting with IGF2BP1. Moreover, the recognition of m⁶A-modified RNAs mediated by IGF2BP1 was partly disturbed by circPTPRA through its interaction with KH domains of IGF2BP1.

Conclusions

This study identifies exonic circular circPTPRA as a new tumor suppressor that inhibits cancer progression through endogenous blocking the recognition of IGF2BP1 to m⁶A-modified RNAs, indicating that circPTPRA may serve as an exploitable therapeutic target for patients with BC.

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

Prasad SM, Decastro GJ, Steinberg GD. Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol. 2011;8(11):631–42. https://doi.org/10.1038/nrurol.2011.144.CrossRefPubMed

Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, et al. Bladder cancer. Lancet (London, England). 2016;388:2796–810.CrossRef

Porten SP. Epigenetic alterations in bladder Cancer. Curr Urol Rep. 2018;19(12):102. https://doi.org/10.1007/s11934-018-0861-5.CrossRefPubMed

Audenet F, Attalla K, Sfakianos JP. The evolution of bladder cancer genomics: what have we learned and how can we use it? Urol Oncol. 2018;36(7):313–20. https://doi.org/10.1016/j.urolonc.2018.02.017.CrossRefPubMed

Lee M, Kim B, Kim VN. Emerging roles of RNA modification: m (6) a and U-tail. Cell. 2014;158(5):980–7. https://doi.org/10.1016/j.cell.2014.08.005.CrossRefPubMed

Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Divon M, et al. Stem cells. m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation. Science (New York, NY). 2015;347:1002–6.CrossRef

Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–8. https://doi.org/10.1038/nature11928.CrossRefPubMed

Rybak-Wolf A, Stottmeister C, Glazar P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58(5):870–85. https://doi.org/10.1016/j.molcel.2015.03.027.CrossRefPubMed

10.

Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–91. https://doi.org/10.1038/s41576-019-0158-7.CrossRefPubMed

11.

Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8. https://doi.org/10.1038/nature11993.CrossRefPubMed

12.

Xie F, Li Y, Wang M, Huang C, Tao D, Zheng F, et al. Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis. Mol Cancer. 2018;17(1):144. https://doi.org/10.1186/s12943-018-0892-z.CrossRefPubMedPubMedCentral

13.

Li H, Yang F, Hu A, Wang X, Fang E, Chen Y, et al. Therapeutic targeting of circ-CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression. EMBO Mol Med. 2019;11:e10835.CrossRefPubMedPubMedCentral

14.

Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in Myogenesis. Mol Cell. 2017;66(1):22–37 e29. https://doi.org/10.1016/j.molcel.2017.02.017.CrossRefPubMedPubMedCentral

15.

Huang R, Zhang Y, Bai Y, Han B, Ju M, Chen B, et al. N (6)-Methyladenosine modification of fatty acid amide hydrolase messenger RNA in circular RNA STAG1-regulated astrocyte dysfunction and depressive-like behaviors. Biol Psychiatry. 2020;88(5):392–404. https://doi.org/10.1016/j.biopsych.2020.02.018.CrossRefPubMed

16.

Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The landscape of circular RNA in Cancer. Cell. 2019;176(4):869–81 e813. https://doi.org/10.1016/j.cell.2018.12.021.CrossRefPubMedPubMedCentral

17.

Nielsen J, Kristensen MA, Willemoes M, Nielsen FC, Christiansen J. Sequential dimerization of human zipcode-binding protein IMP1 on RNA: a cooperative mechanism providing RNP stability. Nucleic Acids Res. 2004;32(14):4368–76. https://doi.org/10.1093/nar/gkh754.CrossRefPubMedPubMedCentral

18.

Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285–95. https://doi.org/10.1038/s41556-018-0045-z.CrossRefPubMedPubMedCentral

19.

Lemm I, Ross J. Regulation of c-myc mRNA decay by translational pausing in a coding region instability determinant. Mol Cell Biol. 2002;22(12):3959–69. https://doi.org/10.1128/MCB.22.12.3959-3969.2002.CrossRefPubMedPubMedCentral

20.

Mongroo PS, Noubissi FK, Cuatrecasas M, Kalabis J, King CE, Johnstone CN, et al. IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2. Cancer Res. 2011;71(6):2172–82. https://doi.org/10.1158/0008-5472.CAN-10-3295.CrossRefPubMedPubMedCentral

21.

Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, et al. Oncogenic role of THOR, a conserved Cancer/testis long non-coding RNA. Cell. 2017;171(7):1559–1572.e20. https://doi.org/10.1016/j.cell.2017.11.040.CrossRefPubMedPubMedCentral

22.

Chen CY, Ezzeddine N, Shyu AB. Messenger RNA half-life measurements in mammalian cells. Methods Enzymol. 2008;448:335–57. https://doi.org/10.1016/S0076-6879(08)02617-7.CrossRefPubMedPubMedCentral

23.

Li Y, Zheng F, Xiao X, Xie F, Tao D, Huang C, et al. CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep. 2017;18(9):1646–59. https://doi.org/10.15252/embr.201643581.CrossRefPubMedPubMedCentral

24.

He Q, Huang L, Yan D, Bi J, Yang M, Huang J, et al. CircPTPRA acts as a tumor suppressor in bladder cancer by sponging miR-636 and upregulating KLF9. Aging. 2019;11(23):11314–28. https://doi.org/10.18632/aging.102530.CrossRefPubMedPubMedCentral

25.

Huang X, Zhang H, Guo X, Zhu Z, Cai H, Kong X. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. J Hematol Oncol. 2018;11(1):88. https://doi.org/10.1186/s13045-018-0628-y.CrossRefPubMedPubMedCentral

26.

Noubissi FK, Elcheva I, Bhatia N, Shakoori A, Ougolkov A, Liu J, et al. CRD-BP mediates stabilization of betaTrCP1 and c-myc mRNA in response to beta-catenin signalling. Nature. 2006;441(7095):898–901. https://doi.org/10.1038/nature04839.CrossRefPubMed

27.

Zhang HL, Eom T, Oleynikov Y, Shenoy SM, Liebelt DA, Dictenberg JB, et al. Neurotrophin-induced transport of a beta-actin mRNP complex increases beta-actin levels and stimulates growth cone motility. Neuron. 2001;31(2):261–75. https://doi.org/10.1016/S0896-6273(01)00357-9.CrossRefPubMed

28.

Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, et al. 5′ UTR m (6) a promotes cap-independent translation. Cell. 2015;163(4):999–1010. https://doi.org/10.1016/j.cell.2015.10.012.CrossRefPubMedPubMedCentral

29.

Ping X-L, Sun B-F, Wang L, Xiao W, Yang X, Wang W-J, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24(2):177–89. https://doi.org/10.1038/cr.2014.3.CrossRefPubMedPubMedCentral

30.

Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang C-M, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49(1):18–29. https://doi.org/10.1016/j.molcel.2012.10.015.CrossRefPubMed

31.

He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. https://doi.org/10.1186/s12943-019-1109-9.CrossRefPubMedPubMedCentral

32.

Noubissi FK, Nikiforov MA, Colburn N, Spiegelman VS. Transcriptional regulation of CRD-BP by c-myc: implications for c-myc functions. Genes Cancer. 2010;1(10):1074–82. https://doi.org/10.1177/1947601910395581.CrossRefPubMedPubMedCentral

33.

Gu W, Wells AL, Pan F, Singer RH. Feedback regulation between zipcode binding protein 1 and beta-catenin mRNAs in breast cancer cells. Mol Cell Biol. 2008;28(16):4963–74. https://doi.org/10.1128/MCB.00266-08.CrossRefPubMedPubMedCentral

34.

Xu Y, Zheng Y, Liu H, Li T. Modulation of IGF2BP1 by long non-coding RNA HCG11 suppresses apoptosis of hepatocellular carcinoma cells via MAPK signaling transduction. Int J Oncol. 2017;51(3):791–800. https://doi.org/10.3892/ijo.2017.4066.CrossRefPubMedPubMedCentral

35.

Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi K, et al. Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. FEBS J. 2014;281(3):802–13. https://doi.org/10.1111/febs.12625.CrossRefPubMed

36.

Wang C, Gu Y, Zhang E, Zhang K, Qin N, Dai J, et al. A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma. Oncogene. 2019;38(10):1611–24. https://doi.org/10.1038/s41388-018-0548-x.CrossRefPubMed

37.

Kristensen LS, Hansen TB, Venø MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555–65. https://doi.org/10.1038/onc.2017.361.CrossRefPubMed

38.

Wachter K, Kohn M, Stohr N, Huttelmaier S. Subcellular localization and RNP formation of IGF2BPs (IGF2 mRNA-binding proteins) is modulated by distinct RNA-binding domains. Biol Chem. 2013;394(8):1077–90. https://doi.org/10.1515/hsz-2013-0111.CrossRefPubMed

39.

Müller S, Bley N, Glaß M, Busch B, Rousseau V, Misiak D, et al. IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic Acids Res. 2018;46(12):6285–303. https://doi.org/10.1093/nar/gky229.CrossRefPubMedPubMedCentral

40.

Chen RX, Chen X, Xia LP, Zhang JX, Pan ZZ, Ma XD, et al. N (6)-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nat Commun. 2019;10(1):4695. https://doi.org/10.1038/s41467-019-12651-2.CrossRefPubMedPubMedCentral

41.

Bi JB, Zhu Y, Chen XL, Yu M, Zhang YX, Li BX, et al. The role of fascin in migration and invasion of urothelial carcinoma of the bladder. Urol Int. 2013;91(2):227–35. https://doi.org/10.1159/000346559.CrossRefPubMed

42.

Bi J, Chen X, Zhang Y, Li B, Sun J, Shen H, et al. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder. Urol Oncol. 2012;30(5):688–94. https://doi.org/10.1016/j.urolonc.2010.08.001.CrossRefPubMed

43.

Xue M, Pang H, Li X, Li H, Pan J, Chen W. Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway. Cancer Sci. 2016;107(1):18–27. https://doi.org/10.1111/cas.12844.CrossRefPubMed

44.

Ou C, Sun Z, He X, Li X, Fan S, Zheng X, et al. Targeting YAP1/LINC00152/FSCN1 signaling Axis prevents the progression of colorectal Cancer. Adv Sci (Weinh). 2020;7(3):1901380. https://doi.org/10.1002/advs.201901380.CrossRef

45.

Gao R, Zhang N, Yang J, Zhu Y, Zhang Z, Wang J, et al. Long non-coding RNA ZEB1-AS1 regulates miR-200b/FSCN1 signaling and enhances migration and invasion induced by TGF-β1 in bladder cancer cells. J Exp Clin Cancer Res. 2019;38(1):111. https://doi.org/10.1186/s13046-019-1102-6.CrossRefPubMedPubMedCentral

46.

Carroll PA, Freie BW, Mathsyaraja H, Eisenman RN. The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis. Front Med. 2018;12(4):412–25. https://doi.org/10.1007/s11684-018-0650-z.CrossRefPubMedPubMedCentral

47.

Mahe M, Dufour F, Neyret-Kahn H, Moreno-Vega A, Beraud C, Shi M, et al. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med. 2018;10(4). https://doi.org/10.15252/emmm.201708163.

48.

Li Y, Xu Z, Wang K, Wang N, Zhu M. Network analysis of microRNAs, genes and their regulation in human bladder cancer. Biomed Rep. 2013;1(6):918–24. https://doi.org/10.3892/br.2013.157.CrossRefPubMedPubMedCentral

49.

Watters AD, Latif Z, Forsyth A, Dunn I, Underwood MA, Grigor KM, et al. Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer. Br J Cancer. 2002;87(6):654–8. https://doi.org/10.1038/sj.bjc.6600531.CrossRefPubMedPubMedCentral

50.

Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M, et al. The m (6) a methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene. 2019;38(19):3667–80. https://doi.org/10.1038/s41388-019-0683-z.CrossRefPubMed

51.

Weidensdorfer D, Stöhr N, Baude A, Lederer M, Köhn M, Schierhorn A, et al. Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. Rna. 2009;15(1):104–15. https://doi.org/10.1261/rna.1175909.CrossRefPubMedPubMedCentral

Title: CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression
Authors: Fei Xie
Chao Huang
Feng Liu
Hui Zhang
Xingyuan Xiao
Jiayin Sun
Xiaoping Zhang
Guosong Jiang
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2021
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-021-01359-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin

Correction to: Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma

m6A target microRNAs in serum for cancer detection

Crosstalk between autophagy and microbiota in cancer progression

The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells

Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer